Key Dates

Related Announcements

• November 05, 2024 - Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional). See PAR-25-104.

Issued by

National Cancer Institute (NCI)

Purpose

This Notice of Correction informs applicants of a correction in the Research Plan section in PAR-25-104, Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional).

The correction to the NOFO is shown below:

Part 2. Full Text of Announcement, Section IV. Application and Submission Information

Currently reads:

Other Plan(s):

All instructions in the How to Apply-Application Guide must be followed, with the following additional instructions:

• All applicants planning research (funded or conducted in whole or in part by NIH) that results in the generation of scientific data are required to comply with the instructions for the Data Management and Sharing Plan. All applications, regardless of the amount of direct costs requested for any one year, must address a Data Management and Sharing Plan.
• A Data Management and Sharing Plan is not applicable for this NOFO.

Corrected/revised to read (2^nd bullet point has been removed):

Other Plan(s):

All instructions in the How to Apply-Application Guide must be followed, with the following additional instructions:

• All applicants planning research (funded or conducted in whole or in part by NIH) that results in the generation of scientific data are required to comply with the instructions for the Data Management and Sharing Plan. All applications, regardless of the amount of direct costs requested for any one year, must address a Data Management and Sharing Plan.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

For cancer prevention, early detection, screening, and symptom management-related clinical trials, contact:
Goli Samimi, Ph.D., M.P.H.
National Cancer Institute (NCI)
Telephone: 240-276-6582
Email: [email protected]

For cancer control and population sciences-related clinical trials including cancer care delivery, contact:
Stephanie Land, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276- 6946
Email: [email protected]

Peer Review Contact(s)

Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: [email protected]

Financial/Grants Management Contact(s)

Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: [email protected]